Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
Core Innovation
The invention provides antibodies that specifically bind the extracellular domain of human T-cell Immunoglobulin Mucin 3 (TIM3). The disclosed antibodies are TIM3-specific and exhibit rapid internalization into TIM3-expressing cancer cells, including cancer stem cells. This enables targeted therapy and diagnostics for subjects having TIM-3 expressing cancer.
The invention addresses a therapeutic need by targeting TIM3-expressing cancer cells and thereby inhibiting tumor cell functions. The disclosed antibody formats include inhibition of tumor cell proliferation under crosslinked/multimerized conditions and complement-dependent cytotoxicity (CDC) mediated via Fc engagement. The invention also includes reduction of release of Th1 inflammatory cytokines, including IFN-γ and IL-6, from activated CD4+ T cells.
The invention further supports a theranostic concept by providing antibody sequences and corresponding functional properties for targeting TIM3-expressing malignancies. The document provides experimental evidence of TIM3 expression across multiple hematologic malignancies and solid tumors and includes patient sample contexts such as B cell lymphoma and acute myeloid leukemia (AML). The invention also describes antibody conjugation options with cytotoxic agents, including ADC formats, for enhanced therapeutic activity.
Claims Coverage
The independent claim is a method claim. It covers administration to a subject of a TIM3-extracellular-domain-binding antibody selected from specified light-chain and heavy-chain CDR sequence sets, delivered as a pharmaceutical composition with a pharmaceutically acceptable carrier. In total, the independent claim defines 5 alternative antibody sequence sets and includes multiple refinements in dependent claims for target cancer categories and antibody formats.
Administering a pharmaceutical composition with TIM3 extracellular-domain binding antibody selected from specified CDR sequence sets
Administering to a subject having a TIM-3 expressing cancer an effective amount of a pharmaceutical composition comprising an antibody that specifically binds the extracellular domain of human T-cell Immunoglobulin Mucin 3 and a pharmaceutically acceptable carrier, wherein the antibody is selected from the group of antibodies defined by specified light chain CDR 1, 2, and 3 sequences and specified heavy chain CDR 1, 2, and 3 sequences.
Claim coverage centers on a method of treating TIM-3 expressing cancer by administering an effective amount of a pharmaceutical composition containing a TIM3 extracellular-domain-specific antibody, where the antibody is defined by particular light- and heavy-chain CDR sequence sets. Dependent refinements further specify cancer categories, including AML, and add structural or functional options such as cross-linked or multimerized antibody formats and conjugation to chemotherapeutic or cytotoxic agents.
Stated Advantages
Enables targeted therapy and diagnostics for TIM3-expressing cancer by using TIM3-specific antibodies that rapidly internalize into TIM3-expressing cancer cells.
Inhibits tumor cell proliferation under crosslinked/multimerized conditions.
Provides complement-dependent cytotoxicity (CDC) via Fc engagement.
Reduces release of Th1 inflammatory cytokines (IFN-γ and IL-6) from activated CD4+ T cells.
Provides antibody conjugation options, including ADC formats, for enhanced therapeutic activity.
Documented Applications
Therapeutic and diagnostic use for subjects having TIM-3 expressing cancer, supported by TIM3 expression across hematologic malignancies and solid tumors.
Targeted therapy contexts including cancer stem cells (CSCs) and TIM3-expressing cancer cells.
Cancer-type contexts explicitly described include B cell lymphoma and acute myeloid leukemia (AML), including patient sample contexts.
Conjugation and therapeutic formats explicitly described include antibody conjugates and ADCs for cytotoxic agents.
Interested in licensing this patent?